FibroBiologics Inc. (NASDAQ: FBLG) completed onboarding of clinical sites for its Phase 1/2 trial evaluating CYWC628 for treating refractory diabetic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE